Automation of hepatitis A and B screening: Comparison of two systems, the Roche COBAS® Core II and the Abbott AxSYM®

Giuseppe Banfi, Erica Makovec, Marie Francoise Beya

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a study in a virology laboratory to assess the performance of the Roche COBAS® Core II immunoanalyzer in comparison to those of the Abbott AxSYM for various hepatitis parameters. An intra-assay imprecision of 4.3%-9.4% was obtained with the COBAS Core HBsAg II EIA, and of 3.1%-5.4% with the COBAS Core HBeAg EIA II. The inter-assay imprecisions were 4.6%-7.8% for the COBAS Core HBsAg II EIA and 2.9%-8.4% for the COBAS Core HBeAg EIA II. No carry over for concentrations up to 75,000 U/mL HBsAg was reported. Generally good agreement was obtained on 100 clinical samples for six parameters: one discrepancy for HBsAg, two for anti-HBs, none for HBeAg, four for anti-HBe, four for anti-HBc IgM and one for anti-HAV IgM. Out of the 95 samples run in parallel in a routine simulation for the same six parameters, five discrepancies were observed for anti-HBs and one for anti-HBe. Additionally, the COBAS Core HBsAg II EIA yielded a specificity of 99.91% and a sensitivity of 100% on 1104 clinical samples. A three day time study did not show any major difference between the COBAS Core II and the AxSYM. In summary, very similar performances were obtained with both systems.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalJournal of Clinical Ligand Assay
Volume22
Issue number2
Publication statusPublished - Jun 1999

Keywords

  • Enzyme immunoassays
  • Hepatitis diagnosis
  • System comparison
  • Virology

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology

Fingerprint

Dive into the research topics of 'Automation of hepatitis A and B screening: Comparison of two systems, the Roche COBAS® Core II and the Abbott AxSYM®'. Together they form a unique fingerprint.

Cite this